share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  07/30 08:05
Moomoo AI 已提取核心信息
On July 30, 2024, 180 Life Sciences Corp. announced positive topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. The study, conducted in collaboration with Prof. Avi Domb of the Hebrew University and Prof. Elyad Davidson of Hadassah Hospital, compared the pharmacokinetic profile of two solid CBD formulations against Epidiolex, an FDA-approved drug for epilepsy. Twelve volunteers participated in a crossover randomized trial, revealing that one of the solid forms was absorbed faster and reached higher maximal levels than Epidiolex, while both solid forms were well tolerated. The company believes that the solid formulation could advance the testing of CBD in other indications, such as pain and PTSD, due to its potential benefits and more desirable pill format. The full study results are pending and are expected to be submitted for scientific publication at a later date. 180 Life Sciences Corp. does not anticipate the trial's outcome to impact its financial results for the year ended December 31, 2024.
On July 30, 2024, 180 Life Sciences Corp. announced positive topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. The study, conducted in collaboration with Prof. Avi Domb of the Hebrew University and Prof. Elyad Davidson of Hadassah Hospital, compared the pharmacokinetic profile of two solid CBD formulations against Epidiolex, an FDA-approved drug for epilepsy. Twelve volunteers participated in a crossover randomized trial, revealing that one of the solid forms was absorbed faster and reached higher maximal levels than Epidiolex, while both solid forms were well tolerated. The company believes that the solid formulation could advance the testing of CBD in other indications, such as pain and PTSD, due to its potential benefits and more desirable pill format. The full study results are pending and are expected to be submitted for scientific publication at a later date. 180 Life Sciences Corp. does not anticipate the trial's outcome to impact its financial results for the year ended December 31, 2024.
2024年7月30日，180 Life Sciences公司宣布了一项新的固体大麻二酚（CBD）增强口服摄取的临床药理学研究的积极上市结果。该研究与希伯来大学的Avi Domb教授和Hadassah医院的Elyad Davidson教授合作进行，比较了两种固体CBD制剂与Epidiolex，一种FDA批准用于癫痫的药物的药代动力学特征。12名志愿者参加了一项交叉随机试验，结果显示其中一种固体形式比Epidiolex吸收更快，达到更高的最大水平，而两种固体形式都很耐受。公司相信，这种固体制剂可以推进CBD在其他适应症中的测试，如疼痛和创伤后应激障碍（PTSD），因为其潜在的益处和更理想的药丸格式。完整的研究结果有待提交科学出版物，并将于以后的日期提交。180 Life Sciences公司不预计该试验结果会影响截至2024年12月31日的财务结果。
2024年7月30日，180 Life Sciences公司宣布了一项新的固体大麻二酚（CBD）增强口服摄取的临床药理学研究的积极上市结果。该研究与希伯来大学的Avi Domb教授和Hadassah医院的Elyad Davidson教授合作进行，比较了两种固体CBD制剂与Epidiolex，一种FDA批准用于癫痫的药物的药代动力学特征。12名志愿者参加了一项交叉随机试验，结果显示其中一种固体形式比Epidiolex吸收更快，达到更高的最大水平，而两种固体形式都很耐受。公司相信，这种固体制剂可以推进CBD在其他适应症中的测试，如疼痛和创伤后应激障碍（PTSD），因为其潜在的益处和更理想的药丸格式。完整的研究结果有待提交科学出版物，并将于以后的日期提交。180 Life Sciences公司不预计该试验结果会影响截至2024年12月31日的财务结果。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息